OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: University of Minnesota

3 Projects | 2 Researchers | $799,846 Invested

2024

University of Minnesota

Karen Ashe, MD, PhD

Targeting Caspase-2 to Repair Synaptic Function in Tauopathies

  • Funding Amount: $493,875
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Active

2022

University of Minnesota

Karen Ashe, MD, PhD

Repairing neurotransmission in Alzheimer's disease and related disorders by targeting caspase-2

  • Funding Amount: $105,971
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Synaptic Activity and Neurotransmitters
  • Status: Closed

2013

University of Minnesota

Ling Li, DVM, PhD

ApoJ/Clusterin Peptide as a Novel Therapeutic Agent for Alzheimer's Disease

  • Funding Amount: $200,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Closed